Cargando…
Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry
BACKGROUND: Despite enormous clinical improvements, due to better management strategies and the availability of biologicals, immune-mediated inflammatory diseases (IMIDs) still have a significant impact on patients’ lives. To further reduce disease burden, provider- as well as patient-reported outco...
Autores principales: | Looijen, Agnes E M, van Linschoten, Reinier C A, Brugma, Jan-Dietert, Hijnen, Dirk Jan, de Jong, Pascal H P, van der Kuy, P Hugo M, van Laar, Jan A M, van der Woude, C Janneke, Pasma, Annelieke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131723/ https://www.ncbi.nlm.nih.gov/pubmed/36995758 http://dx.doi.org/10.2196/43230 |
Ejemplares similares
-
Impact of the First SARS-CoV-2 Lockdown on Adherence to Biological Treatment in Patients with Immune-Mediated Inflammatory Diseases in the Netherlands
por: van der Groef, Romy, et al.
Publicado: (2023) -
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2021) -
Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
por: Paulides, Emma, et al.
Publicado: (2021) -
Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2023) -
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
por: Dane, Aniek, et al.
Publicado: (2023)